Vitex agnus-castus in Nutritional Pharmacology: Endocrine Regulatory Mechanisms and Symptom-Oriented Clinical Applications From Dopaminergic and Hypothalamic-Pituitary-Gonadal Axis Modulation to Hormonal Homeostasis

Abstract Background: Cognitive fatigue, anxiety, insomnia, PMS/PMDD, and perimenopausal complaints share a common pathophysiology: a coupled breakdown across neurotransmission, endocrine feedback, and cellular energetics. This work integrates basic, translational, and clinical evidence to position Vitex agnus-castus (Vitex) as a systems-level modulator within a neuro–endocrine–metabolic framework. Objective: To synthesize the full mechanistic and clinical scope of Vitex - spanning dopaminergic, serotonergic, and GABAergic signaling; HPA/HPG axes; mitochondrial bioenergetics and antioxidant defenses; neurotrophic/synaptic plasticity; objective neurophysiology and sleep architecture; safety; and nutrient synergies - into an actionable model for functional nutritional psychiatry. Approach: Narrative integration of in vitro, in vivo, neuroimaging, and randomized clinical data across seven domains:(1) neurotransmission-energy interconnection; (2) energy substrates and metabolic synergy; (3) mitochondrial homeostasis/antioxidant defense; (4) HPA–mitochondrial crosstalk and cortisol regulation; (5) neurotrophic upregulation and synaptic plasticity; (6) integrated reconstruction of neuro–energy–hormonal systems; (7) anxiety/neuro-stress mechanisms and outcomes. Clinical metrics include PSQI/ISI, HAM-A/POMS, endocrine panels (cortisol, prolactin, progesterone), neurotrophic (BDNF), redox/energetic markers, EEG/PSG, FDG-PET, and fMRI connectivity. Key mechanistic findings: l Neurotransmission-energy coupling: Vitex acts as a partial D₂ agonist to reduce prolactin and restore mesocorticolimbic dopaminergic tone (motivation/executive control), enhances 5-HT synthesis and 5-HT₁A sensitivity (affect and circadian stability), and increases GABA_A responsiveness while promoting glutamate → GABA conversion (anti-hyperarousal). These changes couple to improved mitochondrial ATP supply, minimizing signal-energy mismatches during cognitive load. l Metabolic optimization: Through AMPK activation and PGC-1α/SIRT1/TFAM signaling, Vitex increases glucose uptake, β-oxidation, mitochondrial biogenesis, and membrane potential (Δψm), while reducing electron-leak–derived ROS. Nrf2–ARE induction elevates SOD/GPx/CAT, establishing a sustained antioxidant “enzyme profile” beyond direct radical scavenging. l HPA–HPG and circadian recalibration: Upstream D₂ activation dampens CRH–ACTH–cortisol throughput and restores negative feedback sensitivity (GR), re-establishing an inverse cortisol-melatonin rhythm. Concurrently, reduced prolactin supports luteal function and endogenous progesterone, bridging HPA–HPG cross-talk relevant to PMS/PMDD and perimenopause. l Neurotrophic and circuit-level repair: Vitex upregulates BDNF via CREB and potentiates TrkB→PI3K-Akt/MAPK-ERK cascades, increasing synapsin I/PSD-95, dendritic spine density, and LTP. At the systems level, fMRI indicates strengthened amygdala–prefrontal anti-correlations, aligning emotional control with executive oversight. Objective outcomes (range across studies/models): decreases in HAM-A (~30%), PSQI/ISI (≈25–32%); normalization of diurnal cortisol (≈20–28% reductions with phase resynchronization) and prolactin; increases in serum 5-HT (~18–25%), GABA (~15–22%), BDNF (~25–45%); EEG alpha↑/beta↓; PSG deep sleep (N3)↑ and REM↑ with fewer awakenings; FDG-PET glucose utilization↑ in PFC/hippocampus; Δψm and ATP↑ with ROS and MDA↓. Nutrient co-factor synergy: Alpha-linolenic acid (ALA) improves membrane fluidity and ETC efficiency; magnesium stabilizes NMDA/GABA_A and Mg-ATP kinetics; zinc supports GAD, SOD, and GR conformational function; vitamin B6 (PLP) accelerates DA/5-HT synthesis. Together they create a “signal–substrate–structure” loop that amplifies Vitex’s effects (faster recovery of energy metrics, stronger synaptic outputs, and greater anti-stress resilience). Clinical indications and measurement: PMS/PMDD, anxiety-related insomnia, perimenopausal mood/sleep disturbance, and stress-linked cognitive fatigue/high workload. Recommended composite endpoints: PSQI/ISI, HAM-A/POMS, sustained attention/working memory tasks, morning–evening cortisol curve, prolactin/progesterone, and serum BDNF, complemented by EEG/PSG and selective fMRI/FDG-PET where feasible. Conclusion: Vitex functions not as a sedative or hormone replacement, but as a neuro–endocrine–metabolic synchronizer: D₂/5-HT/GABA rebalancing, AMPK-driven mitochondrial optimization with Nrf2 antioxidant defense, HPA/HPG and circadian resynchronization, and BDNF-guided synaptic/circuit regeneration. Implemented alone or with ALA–Mg–Zn–B6, it provides an evidence-aligned, measurable path from symptom relief to homeostatic restoration and neural resilience, advancing the agenda of functional nutritional psychiatry.